Inlyta (axitinib; Pfizer) is a kinase inhibitor designed to selectively inhibit vascular endothelial growth factor receptor-1 (VEGFR-1), VEGFR-2, and VEGFR-3. These receptors are believed to be implicated in angiogenesis, tumor growth, and metastasis.
Inlyta was approved by the US Food and Drug Administration (FDA) in January 2012 for use in the treatment of patients with advanced renal cell cancer (RCC) after failure of one prior systemic therapy (Pfizer press release, 2012a). Inlyta subsequently received EU marketing authorization for the treatment of advanced RCC after failure of prior treatment with Sutent (sunitinib; Pfizer) or a cytokine (Pfizer press release, 2012b). These approvals were based on the results of a head-to-head Phase III trial with Nexavar (sorafenib; Bayer/Amgen), an established therapy in the second-line treatment of advanced RCC.
LIST OF FIGURES
12 Figure 1: Inlyta for RCC – SWOT analysis
13 Figure 2: Datamonitor Healthcare’s drug assessment summary of Inlyta for RCC
14 Figure 3: Datamonitor Healthcare’s drug assessment summary of Inlyta for RCC
16 Figure 4: Inlyta sales for RCC across the US, Japan, and five major EU markets, by country, 2017–26
LIST OF TABLES
5 Table 1: Inlyta drug profile
7 Table 2: Inlyta Phase III data in RCC
9 Table 3: Inlyta Phase III data in RCC
11 Table 4: Inlyta Phase III data in RCC
17 Table 5: Inlyta sales for RCC across the US, Japan, and five major EU markets, by country ($m), 2017–26
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.